Article
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
The Lancet. Oncology - 1 Jan 2022
Wen Patrick Y, Stein Alexander, van den Bent Martin, De Greve Jacques, Wick Antje, de Vos Filip Y F L, von Bubnoff Nikolas, van Linde Myra E, Lai Albert, Prager Gerald W, Campone Mario, Fasolo Angelica, Lopez-Martin Jose A, Kim Tae Min, Mason Warren P, Hofheinz Ralf-Dieter, Blay Jean-Yves, Cho Daniel C, Gazzah Anas, Pouessel Damien, Yachnin Jeffrey, Boran Aislyn, Burgess Paul, Ilankumaran Palanichamy, Gasal Eduard, Subbiah Vivek
Abstract excerpt
BACKGROUND: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive high-grade glioma and low-grade glioma. METHODS: This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.